BIOGEN INC (BIIB)

US09062X1037 - Common Stock

194.285  -0.09 (-0.05%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

BIOGEN INC

NASDAQ:BIIB (4/22/2024, 9:54:05 AM)

194.285

-0.09 (-0.05%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap28.24B
Shares
PE12.88
Fwd PE12.33
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

BIIB Daily chart

Company Profile

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 8,725 full-time employees. The firm is focused on discovering, developing and delivering therapies for people living with serious and complex diseases worldwide. The company has a portfolio of medicines to treat multiple sclerosis, spinal muscular atrophy (SMA) and Alzheimer's disease. The company is focused on advancing its pipeline in neurology, neuropsychiatry, specialized immunology and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; FUMADERM for the treatment of severe plaque psoriasis, and SKYCLARYS (omaveloxolone). The company is also advancing its mid-to-late stage programs, including zuranolone for major depressive disorder (MDD) and postpartum depression (PPD); BIIB080 for Alzheimer's disease; tofersen for amyotrophic lateral sclerosis (ALS), and both litifilimab and dapirolizumab pegol for certain forms of lupus.

Company Info

BIOGEN INC

225 Binney Street

Cambridge MASSACHUSETTS 02142

P: 17814642000

CEO: Michel Vounatsos

Employees: 8725

Website: https://www.biogen.com/

BIIB News

News Image10 days ago - Market News VideoNasdaq 100 Movers: AMD, FANG
News Image11 days ago - Market News VideoBIIB May 31st Options Begin Trading
News Image12 days ago - Market News VideoBiogen Enters Oversold Territory (BIIB)
News Image18 days ago - Market News VideoBIIB May 24th Options Begin Trading
News Image22 days ago - Eisai Inc.Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA

/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...

News Image25 days ago - Investor's Business DailyRace To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback

The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.

BIIB Twits

Here you can normally see the latest stock twits on BIIB, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example